IHL or IRX?, page-112

And there you have it, confirmation that IRX is dreaming bigger and wants to be a Bio-tech and rub shoulders with its older brother IHL, but with its own unique spin...

IHL playbook handed down to IRX:

• Both companies using 505(b)(2) pathway for accelerated approval with the FDA
• Both engaging Camargo for IND package
• Whilst IHL had its oils business to spin short term cash, IRX has its white label sales of Medihale device and refill pods, but please note this will unlikely be the key driver of any significant inflection point, it is the novel drug combinations that should be the focus of investors valuation models
• IRX chose these conditions as they are two unsolved medical needs that require ultra fast onset and highly efficacious medication -> "No drugs havebeen specifically approved for CRPS" and "There are currently no effective treatments for PD", this rings a lot of bells from Dr Suds Small Cats Interview in 2020 on IHL, see below:
• Would not be surprised should a NASDAQ listing be on the cards down the track, or anything else IHL has done we can expect these ideas to be thrashed out in IRX due to the cross-over in management well highlighted by Sapporo

A couple of distinguishing factors from IHL

• IRX also has orphan drug designation for its candidates
• IRX was the first to market with Medihale (vape hardware). EC Pharma and other licenced producers are responsible for the filling component with the Active Ingredient component. The formulation scope of work for the clinical trials is being coordinated by IRX, and therefore, any associated IP will be owned by IRX

Why IRX?
There have been attempts made historically by competitors to create inhalation drug / device combination medications, however, none have been successful and CRPS / PD has never been targeted for inhalation/cannabinoids either.

This is a great time to load up should you be willing to hold for the long term, Darryl has already clearly got things moving from the achievements listed in current announcements, but IRX is still a ways away from the results of a company making PH2 trial, which really, is what all this is about if you want to 20x your money. Would expect more interest once trials start